Sobimetinib, trametinib, binimetinib, and selumetinib are the four drugs currently approved as MEK inhibitors by the FDA for use in the treatment of neurofibromatosis type 1 in children and other cancers with constitutively active MEK and ERK [15,21]. Here, MAP2K7 is linked to cancer.